Suppr超能文献

在中国人群中,BRAF V600E 可作为补充细针穿刺(FNA)细胞学的准确标志物,指导甲状腺手术:来自 1000 多例连续 FNA 及随访的证据。

BRAF V600E as an accurate marker to complement fine needle aspiration (FNA) cytology in the guidance of thyroid surgery in the Chinese population: evidence from over 1000 consecutive FNAs with follow-up.

机构信息

Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou.

Department of Pathology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

出版信息

Jpn J Clin Oncol. 2021 Apr 1;51(4):590-594. doi: 10.1093/jjco/hyaa209.

Abstract

BACKGROUND

Currently, several commercial molecular tests have been developed for reclassifying thyroid nodules with indeterminate fine needle aspiration cytology. These tests are quite expensive and not available in China. Previous studies demonstrated a very high prevalence of the BRAF V600E mutation in Asian people. A high incidence may result in a robust sensitivity. We conducted this study to determine the prevalence of BRAF V600E mutation and its ability to reclassify cytologically indeterminate thyroid nodules in the Chinese population.

METHODS

Between January 2016 and October 2018, consecutive patients who underwent a fine needle aspiration procedure and agreed to provide materials for molecular analysis in our hospital were recruited in this study. All were followed up until they had a thyroidectomy and a final pathological diagnosis or until January 2019 (those did not have surgery).

RESULTS

A total of 1960 patients were included in this study. Until January 2019, 1240 patients underwent surgery. Using histopathological diagnosis as a gold standard, the overall sensitivity and specificity of the BRAF V600E mutational analysis for the discrimination of benign nodules from cancer in thyroid fine needle aspiration samples were 83.3% (81.0-85.3%) and 96.0% (77.7-99.8%), respectively, with an area under the ROC curve of 0.90 (95% CI 0.85-0.95, P < 0.001). Among cases with indeterminate cytology, BRAF-positive cases were showing malignancy in the final pathology, and BRAF-negative cases were showing safer to be followed up.

CONCLUSION

The BRAF V600E mutation is highly prevalent in the Chinese population and can accurately complement cytopathology in the guidance of thyroid surgery.Mini-abstract: The BRAF V600E mutation has both high specificity and sensitivity to predict thyroid malignancy in the Chinese population. It can accurately complement cytopathology in the guidance of thyroid surgery.

摘要

背景

目前,已经开发出几种商业分子检测方法,用于重新分类细针穿刺细胞学检查结果为不确定的甲状腺结节。这些检测方法非常昂贵,并且在中国不可用。先前的研究表明,亚洲人群 BRAF V600E 突变的发生率非常高。高发生率可能导致检测具有很强的敏感性。我们进行这项研究旨在确定 BRAF V600E 突变在中国人群中的流行率及其对细胞学不确定的甲状腺结节进行重新分类的能力。

方法

在 2016 年 1 月至 2018 年 10 月期间,连续招募在我院接受细针抽吸术且同意提供分子分析材料的患者参加本研究。所有患者均随访至行甲状腺切除术和最终病理诊断,或随访至 2019 年 1 月(未手术的患者)。

结果

本研究共纳入 1960 例患者。截至 2019 年 1 月,1240 例患者接受了手术。以组织病理学诊断为金标准,BRAF V600E 突变分析对甲状腺细针抽吸样本中良恶性结节的鉴别诊断的总体敏感性和特异性分别为 83.3%(81.0-85.3%)和 96.0%(77.7-99.8%),ROC 曲线下面积为 0.90(95%CI 0.85-0.95,P<0.001)。在细胞学不确定的病例中,BRAF 阳性病例在最终病理中表现为恶性,而 BRAF 阴性病例更适合随访。

结论

BRAF V600E 突变在中国人群中高度流行,可准确补充甲状腺手术指导中的细胞病理学。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验